Paxillin confers resistance to tyrosine kinase inhibitors in EGFR-mutant lung cancers via modulating...
Paxillin confers resistance to tyrosine kinase inhibitors in EGFR-mutant lung cancers via modulating BIM and Mcl-1 protein stability
About this item
Full title
Publisher
London: Nature Publishing Group UK
Journal title
Language
English
Formats
Publication information
Publisher
London: Nature Publishing Group UK
Subjects
More information
Scope and Contents
Contents
Tyrosine kinase inhibitors (TKIs) have been documented to have substantial clinical benefits to non-small cell lung cancer with epidermal growth factor receptor (EGFR) mutation. TKI resistance occurs in nearly all patients who receive TKI-targeting therapy, resulting in a modest overall survival benefit. Therefore, establishing a biomarker for earl...
Alternative Titles
Full title
Paxillin confers resistance to tyrosine kinase inhibitors in EGFR-mutant lung cancers via modulating BIM and Mcl-1 protein stability
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_1768574776
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_1768574776
Other Identifiers
ISSN
0950-9232
E-ISSN
1476-5594
DOI
10.1038/onc.2015.120
